A clinical case of amiodarone- and statin-induced neuropathy with a manifestation of chronic inflammatory demyelinating polyneuropathy
- Authors: Zaslavskii L.1,2, Zaslavskaya E.1,2, Petrov M.2, Skornyakova E.2
-
Affiliations:
- I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
- Leningrad Regional Clinical Hospital
- Issue: Vol 34, No 3 (2023)
- Pages: 79-83
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/373107
- DOI: https://doi.org/10.29296/25877305-2023-03-17
- ID: 373107
Cite item
Open Access
Access granted
Abstract
The paper analyzes the data available in the scientific literature on the frequency and manifestations of the neurotoxic effect of amiodarone and statins on the peripheral nervous system. It shows the need for a differential diagnosis with immune-mediated polyneuropathies. The authors provide a rationale for the early identification of the neurotoxicity of the drugs to minimize neurological complications. The paper describes a clinical case of a 72-year-old male patient who received amiodarone and statins and developed demyelinating polyneuropathy. Amiodarone discontinuation led to a significant regression of neurological complaints.
Full Text
About the authors
L. Zaslavskii
I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia; Leningrad Regional Clinical Hospital
Author for correspondence.
Email: Dr.kzaslavskaya@gmail.com
Professor, MD
Russian Federation, Saint Petersburg; Saint PetersburgE. Zaslavskaya
I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia; Leningrad Regional Clinical Hospital
Email: Dr.kzaslavskaya@gmail.com
Candidate of Medical Sciences
Russian Federation, Saint Petersburg; Saint PetersburgM. Petrov
Leningrad Regional Clinical Hospital
Email: Dr.kzaslavskaya@gmail.com
Russian Federation, Saint Petersburg
E. Skornyakova
Leningrad Regional Clinical Hospital
Email: Dr.kzaslavskaya@gmail.com
Russian Federation, Saint Petersburg
References
- Goedee H.S., Attarian S., Kuntzer T. et al. Iatrogenic immune-mediated neuropathies: diagnostic, epidemiological and mechanistic uncertainties for causality and implications for clinical practice. J Neurol Neurosurg Psychiatry. 2021; 92 (9): 975–82. doi: 10.1136/jnnp-2019-321663
- Colvin L.A. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? Pain. 2019; 160 (Suppl 1): S1–S10. doi: 10.1097/j.pain.0000000000001540
- Jones M.R., Urits I., Wolf J. et al. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol. 2020; 15 (1): 38–48. doi: 10.2174/1574884714666190121154813
- Iqbal Z., Bashir B., Ferdousi M. et al. Lipids and peripheral neuropathy. Curr Opin Lipidol. 2021; 32 (4): 249–57. doi: 10.1097/MOL.0000000000000770
- Pathak N.N., Balaganur V., Lingaraju M.C. et al. Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels. Neurochemistry International. 2014; 68: 1–9. doi: 10.1016/j.neuint.2014.01.014
- Graveline D. Adverse Effects of statin drugs: a physician patient’s perspective. J Am Phys Surg. 2015; 20: 7–11.
- Svendsen T.K., Krøigård T., Wirenfeldt M. et al. Statin use and peripheral nerve function – A prospective follow-up study. Basic Clin Pharmacol Toxicol. 2020; 126 (3): 203–11. doi: 10.1111/bcpt.13320
- Sivyakova O.N., Shmanova N.Y., Duleba A.P. A clinical case of multiple amiodarone side effects development. Consilium Medicum. 2018; 20 (5): 71–4 (in Russ.). doi: 10.26442/2075-1753_2018.5.71-74
- Jain K.K. Drug-induced peripheral neuropathies. Drug-induced neurological disorders. Springer, Cham, 2021; рр. 437–67.
- Pizova N.V. Main metabolic and toxic polyneuropathies in clinical practice. Medical Council. 2021; 19: 134–46 (in Russ.). doi: 10.21518/2079-701X-2021-19-134-146
- Mach F. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290: 140–205. doi: 10.1016/j.atherosclerosis.2019.08.014
- Sitkali I.V., Chirichkin A.S., Kolokolov O.V. Affection of peripheral nervous system associated with drug taking. Lechaschi Vrach. 2019; 5: 19 (in Russ.).
- Siao P., Kaku M. A clinician's approach to peripheral neuropathy. Semin Neurol. 2019; 39 (5): 519–30. doi: 10.1055/s-0039-1694747
- Skornyakova E.A., Zaslavskii L.G., Lapin S.V. et al. Opyt opredeleniya antitel k gangliozidam pri vospalitel'nykh polinevropatiyakh. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019; 119 (5-2): 268–9 (in Russ.).
- Ryan M., Ryan S.J. Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health. Am J Manag Care. 2018; 24 (17 Suppl.): S371–9.
Supplementary files
